FlowCardia, Inc. Launches FlowMate™ Injector to Optimize Performance - Gilde Healthcare

FlowCardia, Inc. Launches FlowMate™ Injector to Optimize Performance

October 6, 2009

SUNNYVALE, Calif. — FlowCardia, Inc., a worldwide leader in the development of endovascular devices for the treatment of chronic total occlusions (CTOs), has launched the FlowMate Injector, which dramatically simplifies central lumen crossing of CTOs using the CROSSER CTO Recanalization Catheter.

FlowMate provides unparalleled convenience by granting full control of the procedure to a physician via a single foot pedal, which initiates FlowMate’s precise saline delivery as well as the Generator which activates the CROSSER catheter. Fixed injector settings are integrated into the FlowMate adding even greater convenience and ease of use. A single IV pole houses both the FlowMate and Generator allowing for complete system integration.

“This is a significant improvement to the CROSSER CTO Recanalization System and it takes most of the learning curve out of the equation,”

said Dr. Cezar Staniloae of St. Vincent’s Hospital in New York.

“Set up is fast and using the new system affords me more time to focus on the patient and specifically, crossing the chronic occlusion with the CROSSER Catheter.”

“We are excited to add this important product to our portfolio and to see the benefits to physicians and patients through enhanced CROSSER Catheter performance,”

said Chris Barys, Chief Operating Officer of FlowCardia.

“FlowMate allows for complete CROSSER catheter system integration and puts the power into the physician’s hands, even when faced with the most difficult CTO’s.”

The CROSSER Catheter is a minimally-invasive endovascular device that utilizes high-frequency, mechanical vibration to facilitate passage through blockages in the peripheral and coronary arteries. It is designed as a frontline therapy to enable central lumen crossing of chronically occluded arteries thereby maximizing physicians’ therapeutic options. Over 7,500 CROSSER Catheter procedures have been performed to date by physicians around the world.

FlowCardia, Inc. is a privately held medical device company established in 2002 to design and manufacture a portfolio of endovascular CTO recanalization products. The CROSSER CTO Recanalization Catheter, steerable support catheters, and Porter guidewires comprise a family of tools which enable physicians to quickly cross chronic total occlusions allowing for subsequent balloon angioplasty, atherectomy, and/or stent placement. Additional information is available on the company’s web site at: www.flowcardia.com.

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V.,...
February 29, 2024

Gilde Healthcare co-leads oversubscribed €54 Million Series B round of Argá Medtech

Argá Medtech, a company developing a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation (AF), announced it closed a €54M oversubscribed Series B raise co-led by Gilde Healthcare with existing investors, Advent...
February 28, 2024

Gilde Healthcare leads $125 Million Equity Financing of Mainstay Medical

Funding to accelerate commercial growth and expand clinical and health economic evidence for ReActiv8® Restorative NeuromodulationTM System Mainstay Medical Holdings plc today announced an equity financing in which it will receive gross proceeds of US$125...
February 27, 2024